Full-Time

Director Advanced Analytics and Data Science

Innovation

Updated on 8/1/2026

BeOne

BeOne

1,001-5,000 employees

Global oncology therapeutics discovery, development, manufacturing

Compensation Overview

$174.6k - $234.6k/yr

+ Annual bonus plan + Discretionary equity awards + Employee Stock Purchase Plan

Remote in USA + 1 more

More locations: San Carlos, CA, USA

Remote

Remote within the US; up to 20% travel may be needed for team meetings, stakeholder workshops, or business reviews.

Category
Data & Analytics (1)
Required Skills
LLM
Python
Data Science
R
SQL
Machine Learning
Electronic Health Records (EHR)
Data Governance

Get referred to BeOne

See people who can refer or advise you

Requirements
  • A BA/BS degree and 10+ years of overall industry experience, including 8+ years in advanced analytics, data science, commercial analytics, medical analytics, clinical operations analytics, business analytics, or a related function within the pharmaceutical, biotech, healthcare, or life sciences sector.
  • Experience translating complex data and analytics into strategic recommendations for senior business stakeholders.
  • Strong understanding of healthcare, medical, clinical, and commercial data sources, including claims, prescription, specialty pharmacy, electronic health records, real-world data, clinical trial operations data, market access, and third-party syndicated datasets.
  • Experience leading analytics initiatives and innovations supporting commercial strategy, omnichannel engagement, patient journey insights, medical engagement, evidence generation, clinical trial feasibility, enrollment, site performance, customer targeting, segmentation, measurement, experimentation, or predictive modeling.
  • Ability to lead cross-functional initiatives and influence stakeholders across business, technology, data, legal, compliance, and vendor teams.
  • Ability to identify high-value artificial intelligence innovation opportunities, support AI-enabled transformation, and translate emerging technologies into practical business, scientific, and operational applications with clear measurement plans.
  • Experience designing measurement approaches for analytics and artificial intelligence initiatives, including key performance indicator definition, experimentation, model monitoring, adoption metrics, and business impact assessment.
  • A bachelor's degree in statistics, data science, economics, engineering, business analytics, computer science, or a related quantitative field, or equivalent practical experience.
Responsibilities
  • Contribute to and help execute the advanced analytics capability and innovation roadmap, aligning analytics investments with priorities across Commercial, Medical Affairs, and Clinical Operations and measurable enterprise outcomes.
  • Identify, pilot, and scale use cases for generative artificial intelligence, agentic artificial intelligence, natural language interfaces, intelligent automation, and decision intelligence across Commercial, Medical Affairs, and Clinical Operations.
  • Develop patient journey and evidence-oriented analytics using longitudinal healthcare data, claims, prescription, specialty pharmacy, electronic health records, clinical trial, real-world data, and other relevant data sources.
  • Design and scale analytics solutions supporting omnichannel engagement, customer segmentation, campaign measurement, field effectiveness, medical engagement, and clinical trial acceleration.
  • Lead the development and deployment of predictive models, machine learning capabilities, next-best-action solutions, and decision-support tools.
  • Build measurement frameworks for analytics and artificial intelligence solutions, including success metrics, test-and-learn design, adoption tracking, performance monitoring, and outcome measurement.
  • Serve as a strategic partner to Commercial, Medical Affairs, and Clinical Operations leaders by translating business, scientific, and operational questions into analytical approaches, data requirements, measurable success criteria, and actionable recommendations.
  • Convert analytics outputs into clear narratives, decision frameworks, and implementation plans for stakeholders at all levels.
  • Partner with IT, Data Engineering, Legal, Privacy, Compliance, Medical, and Clinical Operations stakeholders to ensure analytics products, AI/machine learning models, and data practices meet applicable expectations.
  • Promote responsible artificial intelligence practices, including transparency, model explainability, bias awareness, human oversight, fit-for-purpose validation, governance, and ongoing performance measurement.
  • Collaborate with internal teams and external vendors to deliver analytics solutions efficiently and with strong organizational adoption.
  • Provide day-to-day leadership, coaching, and guidance to data scientists, analysts, analytics partners, and external resources.
  • Establish operating models, standards, and best practices that improve analytics quality, scalability, speed to insight, measurement consistency, and reuse across teams.
  • Increase analytics literacy, build stakeholder confidence, and embed insights into commercial planning, medical strategy, evidence generation, and clinical operations execution.
  • Identify opportunities to modernize tools, platforms, processes, and AI-enabled workflows.
  • This position may manage internal analysts, external vendors, agency partners, or contractors and may provide project leadership, coaching, or matrixed guidance to junior analysts; direct people management may be required based on business need.
  • Travel up to 20% may be needed for team meetings, stakeholder workshops, or business reviews.
Desired Qualifications
  • An advanced degree, such as a Master's, MBA, or Ph.D., in a quantitative, scientific, technology, or business discipline.
  • Experience with modern analytics, artificial intelligence, and data platforms, including cloud data warehouses, data science workbenches, business intelligence tools, SQL, Python, R, machine learning operations, generative artificial intelligence tools, experimentation platforms, and AI/machine learning deployment and monitoring approaches.
  • Experience building or scaling analytics capabilities, AI innovation pilots, measurement programs, or test-and-learn frameworks in a fast-paced, growth-oriented organization.
  • Strong executive communication skills, including the ability to develop clear narratives, simplify complexity, and present insights to senior leadership.
  • Familiarity with pharmaceutical data privacy, compliance, governance, responsible artificial intelligence considerations, and the practical application of artificial intelligence in regulated life sciences environments.

BeOne Medicines develops and commercializes cancer therapies for patients worldwide, focusing on hematologic cancers and solid tumors. Its products, including Brukinsa, are sold globally and supported by licensing partnerships, with internal R&D and clinical development driving a broad late-stage pipeline. BeOne differentiates itself by leveraging a large-scale clinical trial network and cost-efficient global drug development to achieve high margins while pursuing large-market indications. The company aims to expand into immunology and solid tumors while maintaining strong investment in R&D to make high-impact, accessible oncology treatments available in more than 45 countries.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Dongcheng District, China

Founded

2010

Get referred to BeOne

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • BRUKINSA and sonrotoclax can expand fixed-duration CLL treatment standards.
  • BGB-43395 and BG-C9074 deepen breast-cancer pipeline optionality.
  • Q1 2026 revenue reached $1.5 billion, supporting broader R&D investment.

What critics are saying

  • Revenue still depends heavily on BRUKINSA, exposing the company to concentration risk.
  • Solid-tumor programs remain early-stage, with limited efficacy and tolerability data.
  • Insider stock sales can pressure sentiment despite the 10b5-1 plan.

What makes BeOne unique

  • Global oncology platform spans hematology, immunology, and solid tumors.
  • BRUKINSA anchors a leading hematology franchise across multiple approved markets.
  • Large global trial network enables faster, more cost-efficient clinical development.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

401(k) Retirement Plan

Wellness Program

Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

-7%

1 year growth

-9%

2 year growth

-3%
Yahoo Finance
Apr 10th, 2026
Amgen's lung cancer drug tarlatamab wins China approval, seen as $2B+ opportunity

Amgen's lung cancer drug tarlatamab has received approval from China's National Medical Products Administration, according to its development partner BeOne Medicines. The drug is a targeted immunotherapy for adults with extensive-stage small cell lung cancer that has progressed despite chemotherapy. Sold as Imdelltra in the US, tarlatamab is a bispecific antibody designed to connect cancer cells with immune cells, enabling the body's immune system to destroy the cancer. Neither Amgen nor Hong Kong-listed BeOne provided details on launch date or pricing for the Chinese market. Wall Street analysts estimate tarlatamab could generate annual sales exceeding $2 billion for Amgen.

Yahoo Finance
Feb 26th, 2026
BeOne Medicines reports $1.5B revenue, up 33% despite EPS miss in Q4

BeOne Medicines reported $1.5 billion in revenue for the quarter ended December 2025, a 32.8% year-over-year increase, beating the Zacks Consensus Estimate by 3.19%. The company posted earnings per share of $0.58, compared to a loss of $1.43 in the prior year, though this fell short of the $1.60 consensus estimate. Net product revenues reached $1.48 billion, exceeding the $1.45 billion analyst estimate. BRUKINSA generated $1.15 billion, surpassing the $1.09 billion estimate, whilst TEVIMBRA contributed $182 million, slightly below the $191.33 million forecast. The stock has returned 0.6% over the past month, matching the S&P 500's performance. BeOne currently holds a Zacks Rank of 2, indicating potential outperformance.

Business Wire
Feb 26th, 2026
BeOne Medicines reports $5.3B full-year revenue as BRUKINSA sales surge 49%

BeOne Medicines reported fourth quarter 2025 product revenues of $1.5 billion and full-year revenues of $5.3 billion, representing growth of 32% and 40% year-over-year respectively. Product revenue accounted for 99% of total revenue. BRUKINSA, the company's BTK inhibitor, achieved global sales of $1.1 billion in Q4 and $3.9 billion for the full year, up 38% and 49% respectively. US sales reached $845 million in Q4 and $2.8 billion annually. TEVIMBRA generated $182 million in Q4 and $737 million for the year. The company reported GAAP net income of $67 million in Q4 and $287 million for the full year, compared to losses in prior-year periods. Free cash flow reached $942 million for 2025, up $1.6 billion year-over-year. BeOne provided 2026 guidance of $6.2–6.4 billion in total revenue and $1.4–1.5 billion in non-GAAP operating income.

Yahoo Finance
Feb 2nd, 2026
BeOne Medicines trades at $340 with 51% annual return amid undervaluation signals

BeOne Medicines is trading at $340.38, representing a 9.44% year-to-date gain and 51.29% total shareholder return over the past year, though recent performance has been mixed with a one-day decline and flat weekly performance. The company appears undervalued against an estimated fair value of $401.52, based on strong revenue growth fundamentals. BeOne reported 41% year-over-year revenue growth in Q2 and raised full-year guidance to $5–5.3 billion, driven by demand for its oncology therapy BRUKINSA. The valuation narrative assumes continued aggressive expansion and rising profitability, supported by an ageing population and increased global healthcare spending. However, risks include potential competition affecting BRUKINSA revenues and possible delays in late-stage trials or regulatory approvals.

TipRanks
Nov 20th, 2025
BeOne Medicines Secures $1 Billion Financing Agreement - TipRanks.com

BeOne Medicines ( ($ONC) ) has shared an announcement. On November 13, 2025, BeOne Medicines Ltd. entered into a Facilities Agreement with HSBC and other financial ...